10-K: ADC Therapeutics SA Details Share Capital, Articles of Association in SEC Filing

ADC Therapeutics SA, a Swiss stock corporation, outlines its share capital structure, registration rights agreements, and articles of association in its latest 10-K filing.

Summary

• ADC Therapeutics SA, a Swiss stock corporation, has filed its annual report on Form 10-K, detailing its share capital and articles of association.
• As of December 31, 2023, the company's share capital consisted of 89,041,946 common shares with a par value of CHF 0.08 per share, with 82,293,137 shares outstanding.
• The company has entered into multiple registration rights agreements with Deerfield Partners, L.P., OR Opportunistic DL (C), L.P., and Oaktree entities, requiring the company to keep registration statements effective for up to three years or until the shares are no longer held by those entitled to registration rights.
• The company's articles of association allow for ordinary capital increases with a majority vote of shares represented at a general meeting, and for conditional share capital of up to 50% of the share capital for issuing shares in connection with option and conversion rights.
• The board of directors is authorized to increase or decrease share capital by up to 50% within a capital range, which is currently set between CHF 7,123,355.68 and CHF 10,685,033.52, until June 14, 2028.
• Shareholders have pre-emptive subscription rights for new share issuances, which can be limited or withdrawn under certain circumstances.
• The company's conditional share capital may be increased by a maximum of CHF 1,432,776.24 for warrants and convertible bonds and by CHF 936,000 for equity incentive plans.
• The company's shares are in the form of uncertificated securities, and shareholders are not entitled to request the conversion and/or printing and delivery of share certificates.
• The general meeting of shareholders is the supreme corporate body, with powers including adopting and amending the articles of association, electing directors and auditors, and approving financial statements.
• Shareholder resolutions and elections require a majority vote, while certain actions such as amending the company's purpose or creating shares with preference rights require a two-thirds majority.
• The company's articles of association contain provisions that prevent investors from acquiring voting rights exceeding 15% of the issued share capital.
• The board of directors consists of at least three and not more than nine members, elected annually by the general meeting of shareholders.
• The board of directors has non-delegable powers and duties including the ultimate direction of the business, setting the organization, and formulating accounting procedures.
• The company has entered into indemnification agreements with its directors and executive officers.
• The company's articles of association provide for indemnification of the existing and former members of the board of directors and the executive committee and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties.
• The company is prohibited from granting certain forms of compensation to members of its board of directors and executive committee, such as severance payments, advance compensation, and incentive fees for acquisitions or transfers of companies.
• The company's ability to repurchase its own shares is limited to 10% of its share capital, or 20% in connection with a transfer restriction set out in the articles of association.
• The company's shares are listed on the NYSE under the symbol ADCT.
• Swiss law applicable to Swiss corporations and their shareholders differs from Delaware law applicable to U.S. corporations and their shareholders, particularly in areas such as mergers, shareholder suits, board compensation, and indemnification of directors.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing factual information about the company's structure and governance. It does not contain any explicit positive or negative statements, but the details provided are important for investors to understand the company's operations.

Positives

• The company has a clear structure for share capital and governance.
• The company has secured registration rights agreements with key investors.
• The company has flexibility in managing its share capital through a capital range.
• The company has provisions for conditional share capital to support future financing and incentive plans.
• The company has a well-defined process for shareholder meetings and voting rights.
• The company has indemnification agreements in place for its directors and executive officers.

Negatives

• The company's articles of association prevent investors from acquiring voting rights exceeding 15% of the issued share capital.
• The company is prohibited from granting certain forms of compensation to members of its board of directors and executive committee, such as severance payments and advance compensation.
• The company's ability to repurchase its own shares is limited to 10% of its share capital, or 20% in connection with a transfer restriction set out in the articles of association.

Risks

• The company's articles of association prevent investors from acquiring voting rights exceeding 15% of the issued share capital.
• The company is prohibited from granting certain forms of compensation to members of its board of directors and executive committee, such as severance payments and advance compensation.
• The company's ability to repurchase its own shares is limited to 10% of its share capital, or 20% in connection with a transfer restriction set out in the articles of association.
• Swiss law applicable to Swiss corporations and their shareholders differs from Delaware law applicable to U.S. corporations and their shareholders, particularly in areas such as mergers, shareholder suits, board compensation, and indemnification of directors.

Future Outlook

The company is required to keep registration statements effective for up to three years or until the shares are no longer held by those entitled to registration rights. The board of directors is authorized to increase or decrease share capital by up to 50% within a capital range until June 14, 2028.

Management Comments

• The board of directors is authorized to increase or decrease share capital by up to 50% within a capital range, which is currently set between CHF 7,123,355.68 and CHF 10,685,033.52, until June 14, 2028.
• The board of directors may in special cases approve exceptions to the restrictions on voting rights.

Industry Context

This filing provides insight into the corporate structure and governance of a Swiss-based biotechnology company, which is relevant for investors and stakeholders in the pharmaceutical industry.

Comparison to Industry Standards

• The company's share capital structure is typical for a Swiss stock corporation.
• The registration rights agreements are common in private equity and venture capital investments.
• The articles of association provisions regarding capital increases and conditional share capital are consistent with Swiss corporate law.
• The board of directors structure and responsibilities are similar to those of other publicly traded companies.
• The limitations on voting rights are a unique feature of this company's governance structure.
• The indemnification agreements are standard practice for publicly traded companies.
• The restrictions on certain forms of compensation for board members and executive committee are specific to Swiss law.
• The limitations on share repurchases are consistent with Swiss corporate law.
• The company's listing on the NYSE is a common practice for international companies seeking access to U.S. capital markets.
• The differences between Swiss and Delaware law highlight the importance of understanding the legal framework of a company's jurisdiction of incorporation.

Corporate Governance

Stakeholder Impact

• Shareholders are impacted by the limitations on voting rights and the potential for dilution from capital increases.
• Employees are impacted by the restrictions on certain forms of compensation for board members and executive committee.
• Creditors are impacted by the limitations on share repurchases.

Next Steps

• The company is required to keep registration statements effective for up to three years or until the shares are no longer held by those entitled to registration rights.
• The board of directors is authorized to increase or decrease share capital by up to 50% within a capital range until June 14, 2028.

Key Dates

Keywords

share capital, articles of association, registration rights, voting rights, board of directors, conditional share capital, pre-emptive rights, capital range, Swiss law, indemnification